CLDX Q4 2019 Earnings — Celldex Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

CLDXCelldex Therapeutics, Inc.

$2B

Q4 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$887,000-49.7% YoY

Gross Profit

-$9M-1065.6% margin

Operating Income

-$13M-1464.4% margin

Net Income

-$10M-1177.8% margin

EPS (Diluted)

$-0.64

QoQ Revenue Growth

+62.5%

Cash Flow

Operating Cash Flow

-$11M

Free Cash Flow

-$11M

Stock-Based Comp.

$687,000

Balance Sheet

Total Assets

$123M

Total Liabilities

$29M

Stockholders' Equity

$94M

Cash & Equivalents

$11M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$887,000	$2M	-49.7%
Gross Profit	-$9M	-$8M	-12.0%
Operating Income	-$13M	-$12M	-7.2%
Net Income	-$10M	-$9M	-11.1%

Revenue Segments

Grant

$793,00089%

Service

$94,00011%